Log in

Urovant Sciences News Headlines (NASDAQ:UROV)

$9.30
+0.08 (+0.87 %)
(As of 10/14/2019 01:23 AM ET)
Today's Range
$9.20
Now: $9.30
$9.49
50-Day Range
$7.72
MA: $9.34
$10.58
52-Week Range
$4.05
Now: $9.30
$14.49
Volume12,275 shs
Average Volume43,931 shs
Market Capitalization$282.16 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Headlines

Urovant Sciences (NASDAQ UROV) News Headlines

Source:
DateHeadline
Zacks: Analysts Anticipate Urovant Sciences Ltd (NASDAQ:UROV) to Post -$1.15 EPSZacks: Analysts Anticipate Urovant Sciences Ltd (NASDAQ:UROV) to Post -$1.15 EPS
www.americanbankingnews.com - October 4 at 5:40 PM
UROV.OQ - Urovant Sciences Ltd Profile | ReutersUROV.OQ - Urovant Sciences Ltd Profile | Reuters
www.reuters.com - October 3 at 9:06 PM
Urovant Sciences Ltd (NASDAQ:UROV) Receives Consensus Recommendation of "Buy" from BrokeragesUrovant Sciences Ltd (NASDAQ:UROV) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - October 1 at 3:35 AM
Urovant Sciences Reports Positive Long-Term Data from the Double-Blind Extension of the Phase 3 EMPOWUR Study of Vibegron in Patients with Overactive BladderUrovant Sciences Reports Positive Long-Term Data from the Double-Blind Extension of the Phase 3 EMPOWUR Study of Vibegron in Patients with Overactive Bladder
finance.yahoo.com - September 24 at 5:29 PM
Urovant Sciences Parent Company, Roivant Sciences, and Sumitomo Dainippon Pharma Enter into a Memorandum of Understanding to Create Broad Strategic AllianceUrovant Sciences Parent Company, Roivant Sciences, and Sumitomo Dainippon Pharma Enter into a Memorandum of Understanding to Create Broad Strategic Alliance
finance.yahoo.com - September 6 at 4:43 PM
Sumitomo Dainippon Pharma and Roivant Sciences...Sumitomo Dainippon Pharma and Roivant Sciences...
www.benzinga.com - September 6 at 8:16 AM
Urovant Sciences Limited (UROV) CEO Keith Katkin on Q1 2019 Results - Earnings Call TranscriptUrovant Sciences Limited (UROV) CEO Keith Katkin on Q1 2019 Results - Earnings Call Transcript
seekingalpha.com - August 14 at 11:13 AM
Urovant Sciences EPS beats by $0.02Urovant Sciences EPS beats by $0.02
seekingalpha.com - August 13 at 8:58 PM
Urovant Sciences Reports 2019 First Fiscal Quarter Financial ResultsUrovant Sciences Reports 2019 First Fiscal Quarter Financial Results
finance.yahoo.com - August 13 at 8:58 PM
Urovant Sciences Ltd (UROV) Q1 2019 Earnings Call TranscriptUrovant Sciences Ltd (UROV) Q1 2019 Earnings Call Transcript
finance.yahoo.com - August 13 at 8:58 PM
Codexis Reports Second Quarter 2019 Financial ResultsCodexis Reports Second Quarter 2019 Financial Results
www.nasdaq.com - August 6 at 9:01 PM
Urovant Sciences to Report 2019 First Fiscal Quarter Financial ResultsUrovant Sciences to Report 2019 First Fiscal Quarter Financial Results
finance.yahoo.com - August 6 at 11:10 AM
Altavant Sciences Initiates Phase 2a Study of Rodatristat Ethyl in Pulmonary Arterial HypertensionAltavant Sciences Initiates Phase 2a Study of Rodatristat Ethyl in Pulmonary Arterial Hypertension
www.benzinga.com - August 5 at 11:36 AM
Here’s What Hedge Funds Think About Urovant Sciences Ltd. (UROV)Here’s What Hedge Funds Think About Urovant Sciences Ltd. (UROV)
finance.yahoo.com - June 30 at 10:46 AM
Urovant Sciences Ltd. (NASDAQ:UROV): Immense Growth Potential?Urovant Sciences Ltd. (NASDAQ:UROV): Immense Growth Potential?
finance.yahoo.com - June 20 at 9:02 AM
Urovant Sciences Reports Financial Results for the Fourth Fiscal Quarter and Full Fiscal Year Ended March 31, 2019Urovant Sciences Reports Financial Results for the Fourth Fiscal Quarter and Full Fiscal Year Ended March 31, 2019
finance.yahoo.com - June 14 at 2:24 PM
Urovant Sciences Ltd. to Host Earnings CallUrovant Sciences Ltd. to Host Earnings Call
finance.yahoo.com - June 13 at 3:47 PM
Urovant Sciences to Report Financial Results for the Fourth Fiscal Quarter and Full Fiscal Year Ended March 31, 2019Urovant Sciences to Report Financial Results for the Fourth Fiscal Quarter and Full Fiscal Year Ended March 31, 2019
finance.yahoo.com - June 6 at 12:10 PM
Urovant up 5% on successful late-stage vibegron studiesUrovant up 5% on successful late-stage vibegron studies
seekingalpha.com - May 6 at 11:53 AM
Urovant Sciences Presents Positive Pivotal Data for Vibegron During Plenary Session at American Urological Association Annual MeetingUrovant Sciences Presents Positive Pivotal Data for Vibegron During Plenary Session at American Urological Association Annual Meeting
finance.yahoo.com - May 6 at 11:53 AM
Urovant Sciences to Present Late-Breaking Data on Vibegron During Plenary Session at the American Urological Association Annual MeetingUrovant Sciences to Present Late-Breaking Data on Vibegron During Plenary Session at the American Urological Association Annual Meeting
finance.yahoo.com - April 29 at 11:47 AM
Urovant Sciences Initiates Phase 3 Clinical Program with Vibegron for Overactive Bladder in Men with Benign Prostatic HyperplasiaUrovant Sciences Initiates Phase 3 Clinical Program with Vibegron for Overactive Bladder in Men with Benign Prostatic Hyperplasia
finance.yahoo.com - March 27 at 11:22 AM
Roivant Statement on Topline Results from EMPOWUR Phase 3 Study in Overactive BladderRoivant Statement on Topline Results from EMPOWUR Phase 3 Study in Overactive Bladder
www.marketwatch.com - March 20 at 8:42 PM
Heres Why Urovant Sciences Got Whacked on "Positive" Clinical Trial DataHere's Why Urovant Sciences Got Whacked on "Positive" Clinical Trial Data
www.fool.com - March 20 at 11:16 AM
Here's Why Urovant Sciences Got Whacked on "Positive" Clinical Trial DataHere's Why Urovant Sciences Got Whacked on "Positive" Clinical Trial Data
finance.yahoo.com - March 20 at 11:16 AM
Urovant up 9% premarket on positive vibregon dataUrovant up 9% premarket on positive vibregon data
seekingalpha.com - March 19 at 3:48 PM
Urovant Sciences Announces Positive Topline Results from Pivotal Phase 3 EMPOWUR Study of Vibegron in Patients with Overactive BladderUrovant Sciences Announces Positive Topline Results from Pivotal Phase 3 EMPOWUR Study of Vibegron in Patients with Overactive Bladder
finance.yahoo.com - March 19 at 3:48 PM
Urovant Sciences LtdUrovant Sciences Ltd
www.bloomberg.com - March 19 at 7:53 AM
Urovant up 1% ahead of vibegron data readoutUrovant up 1% ahead of vibegron data readout
seekingalpha.com - March 19 at 7:53 AM
Urovant Sciences to Announce Topline Results from the EMPOWUR Phase 3 Study of Vibegron in Patients with Overactive BladderUrovant Sciences to Announce Topline Results from the EMPOWUR Phase 3 Study of Vibegron in Patients with Overactive Bladder
finance.yahoo.com - March 19 at 7:53 AM
Urovant Sciences claws back to debut priceUrovant Sciences claws back to debut price
seekingalpha.com - March 14 at 3:40 PM
Urovant Sciences to Present at the Cowen and Company 39th Annual Healthcare ConferenceUrovant Sciences to Present at the Cowen and Company 39th Annual Healthcare Conference
finance.yahoo.com - March 7 at 10:40 AM
Urovant Sciences Appoints James Robinson to its Board of DirectorsUrovant Sciences Appoints James Robinson to its Board of Directors
finance.yahoo.com - March 6 at 10:42 AM
Urovant Sciences (UROV) CEO Keith Katkin on Q3 2018 Results - Earnings Call TranscriptUrovant Sciences (UROV) CEO Keith Katkin on Q3 2018 Results - Earnings Call Transcript
seekingalpha.com - February 14 at 10:00 AM
Urovant Sciences Reports Financial Results for the Third Fiscal Quarter Ended December 31, 2018Urovant Sciences Reports Financial Results for the Third Fiscal Quarter Ended December 31, 2018
finance.yahoo.com - February 14 at 10:00 AM
Urovant Sciences to Report 2018 Third Fiscal Quarter Financial ResultsUrovant Sciences to Report 2018 Third Fiscal Quarter Financial Results
finance.yahoo.com - February 6 at 9:55 AM
Urovant Sciences to Host R&D Day for Investors and Analysts on February 7, 2019Urovant Sciences to Host R&D Day for Investors and Analysts on February 7, 2019
finance.yahoo.com - January 15 at 9:33 AM
Urovant Sciences Initiates Patient Enrollment in Phase 2a Clinical Trial for Vibegron in Patients with Abdominal Pain Due to Irritable Bowel SyndromeUrovant Sciences Initiates Patient Enrollment in Phase 2a Clinical Trial for Vibegron in Patients with Abdominal Pain Due to Irritable Bowel Syndrome
finance.yahoo.com - January 3 at 8:36 AM
Urovant Sciences Ltd (UROV.OQ)Urovant Sciences Ltd (UROV.OQ)
www.reuters.com - December 19 at 8:10 AM
Urovant Sciences to Present at the J.P. Morgan 37th Annual Healthcare ConferenceUrovant Sciences to Present at the J.P. Morgan 37th Annual Healthcare Conference
finance.yahoo.com - December 19 at 8:10 AM
Urovant Sciences Ltd.Urovant Sciences Ltd.
www.barrons.com - December 11 at 3:24 PM
Urovant Sciences Announces Participation in Piper Jaffray Healthcare ConferenceUrovant Sciences Announces Participation in Piper Jaffray Healthcare Conference
finance.yahoo.com - November 19 at 3:18 PM
Dermavant Appoints Todd Zavodnick as Chief Executive OfficerDermavant Appoints Todd Zavodnick as Chief Executive Officer
www.prnewswire.com - November 15 at 3:18 PM
BRIEF-Urovant Sciences Reports Qtrly Loss Per Share $1.23BRIEF-Urovant Sciences Reports Qtrly Loss Per Share $1.23
www.msn.com - November 13 at 6:19 AM
Urovant Sciences (UROV) Reports Q2 Loss of $1.23Urovant Sciences (UROV) Reports Q2 Loss of $1.23
www.streetinsider.com - November 13 at 6:19 AM
Urovant Sciences Reports Financial Results for the Second Fiscal Quarter Ended September 30, 2018 and Provides Corporate UpdateUrovant Sciences Reports Financial Results for the Second Fiscal Quarter Ended September 30, 2018 and Provides Corporate Update
finance.yahoo.com - November 13 at 6:19 AM
Urovant completes enrollment in late-stage study of vibegron for overactive bladder; shares up 2%Urovant completes enrollment in late-stage study of vibegron for overactive bladder; shares up 2%
seekingalpha.com - November 8 at 3:19 PM
Urovant Sciences Completes Patient Enrollment in Phase 3 Pivotal Trial Studying Vibegron for Overactive BladderUrovant Sciences Completes Patient Enrollment in Phase 3 Pivotal Trial Studying Vibegron for Overactive Bladder
finance.yahoo.com - November 8 at 3:19 PM
Urovant Sciences to Report 2018 Second Fiscal Quarter Financial ResultsUrovant Sciences to Report 2018 Second Fiscal Quarter Financial Results
finance.yahoo.com - November 5 at 8:55 AM
Urovant Sciences (UROV) Reports Publication of Phase 2b Data for Vibegron in European UrologyUrovant Sciences (UROV) Reports Publication of Phase 2b Data for Vibegron in European Urology
www.streetinsider.com - November 2 at 6:18 AM
This page was last updated on 10/14/2019 by MarketBeat.com Staff

Featured Article: Range Trading

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel